QUEBEC CITY, Aug. 27, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) announced today that it will release its third quarter
2013 results on September 4, 2013, at 4:00 p.m. (EDT). DiagnoCure's
management will host a conference call the same day, at 4:30 p.m.
(EDT). Interested participants may listen to the call by dialing
1-888-390-0546 or 514-225-6995 and referencing code 78274536
approximately 15 minutes prior to the call. The Corporation will also
provide a live webcast of the call. Interested participants may access
the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations. A replay of the
webcast will be available on DiagnoCure's website for those unable to
participate in the live webcast.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license on PCA3 to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test,
DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the United States. For
more information, please visit www.diagnocure.com.
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.